The approval of the first-line lung cancer indication for Merck & Co. Inc.’s PD-1 inhibitor Keytruda in just four months – two months before the user fee goal date – shows that FDA’s Office of Hematology and Oncology Products is still willing and able to meet its unofficial internal deadline for early action for major approvals.
With some of the most significant product reviews across the agency under its purview, OHOP set up its own internal...





